The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Let's take a look at what these Wall Street heavyweights have to say about Adma Biologics (ADMA) before we discuss the reliability of brokerage recommendations and how to use them to your advantage.Adma Biologics currently ha ...

In the latest market close, Adma Biologics (ADMA) reached $10.84, with a -1.54% movement compared to the previous day. This change lagged the S&P 500's 0.16% gain on the day. Elsewhere, the Dow saw an upswing of 0.04%, while the tech-heavy Nasdaq appreciated by 0.49%.The the stock of infectious disease drug developer has risen by 15.77% in the past month, leading the Medical sector's gain of 2.32% and the S&P 500's gain of 3.22%.The upcoming earnings release of Adma Biologics will be of great interest to in ...

Adma Biologics (ADMA) closed the latest trading day at $10.71, indicating a +0.85% change from the previous session's end. The stock's performance was ahead of the S&P 500's daily loss of 0.25%. Elsewhere, the Dow saw an upswing of 0.77%, while the tech-heavy Nasdaq depreciated by 0.79%.Coming into today, shares of the infectious disease drug developer had gained 10.28% in the past month. In that same time, the Medical sector gained 0.03%, while the S&P 500 gained 3.59%.Analysts and investors alike will be ...

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price. Do they really matter, though?Before we discuss the reliability of brokerage recommendations and how to use them to your advantage, let's see what these Wall Street heavyweights think about Adma Biologics (ADMA) .Adma Biologics currently has an average br ...

Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Titanium Metal Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering.The global titanium metal market is expected to reach an estimated $2.4 billion by 2030 with a CAGR of 5.8% from 2024 to 2030.The major drivers for this market are rising use of titanium dioxide in the paints & coating industry, growing use of titanium metal in the aerospace & defense industry, as well as, increasing deman ...

The 15-month bull run of U.S. stock markets suffered a surprise setback in April. We believe that April’s meltdown was nothing but a bull market correction, and this time a welcome one, as Wall Street has rebounded in May.The Department of Labor reported that the U.S. economy added 175,000 jobs in April, missing the consensus estimate of 200,000. Job additions in March were revised upward by 12,000 while those in February were revised downward by 34,000. The unemployment rate increased to 3.9% in April, com ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma Biologics (ADMA) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Adma Biologics is a member of the Medical sector. This group includes 1048 individual stocks and currently holds a Zacks Sector Rank of #5. The Zacks Sector Rank considers 1 ...

ADMA Biologics, Inc. (NASDAQ:ADMA) Q1 2024 Earnings Conference Call May 9, 2024 4:30 AM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - President and CEO Brian Lenz - Executive Vice President, Chief Financial Officer and General Manager, ADMA BioCenters Conference Call Participants Anthony Petrone - Mizuho Group Kristen Kluska - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon, and welcome to the ADMA Biologics First Q ...

Adma Biologics (ADMA) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.05 per share. This compares to loss of $0.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 60%. A quarter ago, it was expected that this infectious disease drug developer would post earnings of $0.02 per share when it actually produced earnings of $0.04, delivering a surprise of 100%.Over the last four quarte ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36728 ADMA BIOLOGICS, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 56-2590442 (State o ...